Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen Inc.
Seagen Inc.
Bristol-Myers Squibb
Institut Bergonié
NuCana plc
Ohio State University Comprehensive Cancer Center
ImmunityBio, Inc.
Merck Sharp & Dohme LLC
Federation Francophone de Cancerologie Digestive
NSABP Foundation Inc
Takeda
University of Cincinnati
Eastern Cooperative Oncology Group
National Cancer Institute, Naples
Ludwig Institute for Cancer Research
Incyte Corporation
GSO Global Clinical Research BV
Alliance for Clinical Trials in Oncology
Fox Chase Cancer Center
National Institutes of Health Clinical Center (CC)
SCRI Development Innovations, LLC
NSABP Foundation Inc
NSABP Foundation Inc
Fox Chase Cancer Center
Albert Einstein College of Medicine
Brown University
Gilead Sciences
Alliance for Clinical Trials in Oncology
M.D. Anderson Cancer Center
NYU Langone Health
Hoffmann-La Roche
Hoffmann-La Roche
Radiation Therapy Oncology Group
Merck KGaA, Darmstadt, Germany
Medical University of Vienna
SCRI Development Innovations, LLC
Takeda
mAbxience Research S.L.
Hoffmann-La Roche
Amgen
Radiation Therapy Oncology Group
SWOG Cancer Research Network
Alliance for Clinical Trials in Oncology
Hoffmann-La Roche
GlaxoSmithKline
Alliance for Clinical Trials in Oncology
Roswell Park Cancer Institute
Hoffmann-La Roche
Hoffmann-La Roche
OHSU Knight Cancer Institute
AstraZeneca